|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.350 HKD | +1.52% |
|
+1.52% | -12.81% |
| 06-11 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 06-11 | Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +1.52% | +1.52% | -7.66% | -14.44% | -12.81% | -16.86% | +11.36% | -41.01% | +111.89% | 10.56B | |
| -0.04% | -1.81% | +12.29% | +14.08% | +5.00% | +39.72% | +148.58% | +404.82% | +1,430.83% | 1,010B | |
| -2.02% | +1.53% | +3.97% | -3.07% | +13.90% | +51.86% | +43.97% | +43.30% | +102.49% | 580B | |
| -2.67% | -0.65% | +5.33% | +0.07% | -3.01% | +16.11% | +63.08% | +91.32% | +266.90% | 402B | |
| -0.46% | 0.00% | +2.22% | +2.00% | -0.34% | +21.28% | +19.14% | -4.27% | +35.95% | 330B | |
| -1.52% | +1.90% | +2.93% | -0.94% | +9.69% | +23.73% | +34.08% | +43.39% | +63.45% | 281B | |
| -1.95% | -4.75% | -3.93% | -8.21% | -4.28% | +20.15% | +14.68% | +58.12% | +249.76% | 280B | |
| -0.57% | +0.62% | -4.55% | +15.60% | -12.19% | -44.67% | -47.65% | +10.63% | +66.53% | 197B | |
| -2.80% | +1.96% | +8.03% | -3.75% | +7.70% | +19.27% | +54.31% | +46.97% | +132.06% | 192B | |
| -3.87% | -3.04% | -4.14% | -14.46% | +1.20% | +12.07% | +57.23% | +82.42% | +49.58% | 156B | |
| -0.46% | +1.89% | +3.06% | -1.90% | +4.84% | +6.99% | -34.33% | -34.06% | -24.96% | 149B | |
| -0.84% | +1.50% | -1.04% | -5.54% | +4.57% | +15.92% | -12.78% | -16.34% | -22.28% | 117B | |
| +2.16% | +1.59% | +2.99% | -3.45% | -0.74% | -0.20% | +28.91% | +138.13% | +395.38% | 113B | |
| -1.37% | -3.09% | +3.14% | -1.11% | -8.68% | -12.97% | -19.62% | -15.02% | +12.24% | 106B | |
| -1.31% | +1.03% | +4.57% | -3.59% | +7.32% | +29.54% | +43.61% | +11.30% | +12.41% | 106B | |
| -0.30% | -1.67% | -8.25% | -20.66% | -9.89% | -0.39% | +78.47% | +67.49% | +507.19% | 76.54B | |
| -.--% | +1.73% | - | - | - | - | - | - | - | 63.66B | |
| +0.12% | +3.29% | -3.20% | -10.31% | +5.23% | +16.99% | +12.24% | +36.15% | +15.61% | 50.12B | |
| -1.26% | +1.70% | -11.86% | -13.12% | -19.62% | -11.15% | +4.09% | -34.38% | +237.36% | 47.41B | |
| +0.33% | +0.41% | -4.90% | -6.02% | -1.89% | +32.13% | -29.90% | -31.76% | -58.34% | 41.16B | |
| Average | -0.71% | +1.01% | -0.05% | -4.15% | -0.74% | +11.55% | +24.71% | +45.12% | +188.64% | 215.5B | |
| Weighted average by Cap. | -0.98% | +0.92% | +4.04% | +1.35% | +2.82% | +23.29% | +55.54% | +125.68% | +435.41% |
- Stock Market
- Stocks
- 1093 Stock
- Sector CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
